ENDRA Life Sciences Reports Positive Feasibility Study Results for TAEUS Liver Fat Quantification Device

ENDRA Life Sciences Inc. has announced encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, a key biomarker in steatotic liver disease (SLD), including MASLD and MASH. According to the company, the TAEUS Liver device demonstrated strong agreement with the current imaging gold standard, MRI-PDFF, across the full spectrum of steatotic liver disease and patient BMI. These results aim to validate the improved performance of the device and inform the design and statistical plan for a pivotal study in consultation with the U.S. Food and Drug Administration (FDA). A second feasibility study is currently underway in London, Ontario, Canada, with completion expected in the coming months. Results from these studies will be discussed with the FDA in pre-submission meetings prior to initiating the pivotal study and are also expected to be submitted for publication in a peer-reviewed medical journal. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120214395) on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)